Alnylam Pharmaceuticals Ownership | Who Owns Alnylam Pharmaceuticals?


OverviewForecastRevenueFinancialsChartTranscripts

Alnylam Pharmaceuticals Ownership Summary


Alnylam Pharmaceuticals is owned by 69.96% institutional investors, 0.42% insiders, and 29.62% retail investors. Fmr is the largest institutional shareholder, holding 12.93% of ALNY shares. Capital Group Growth Fnd of Amer Comp is the top mutual fund, with 7.40% of its assets in Alnylam Pharmaceuticals shares.

ALNY Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockAlnylam Pharmaceuticals69.96%0.42%29.62%
SectorHealthcare Stocks 231.98%10.74%-142.72%
IndustryBiotech Stocks 381.47%10.55%-292.02%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Fmr16.77M12.93%$7.65B
Capital world investors16.30M12.40%$6.48B
Vanguard group13.55M10.31%$5.39B
Blackrock funding, inc. /de10.40M7.91%$4.14B
Blackrock9.55M7.57%$2.32B
Capital research global investors6.78M5.16%$2.70B
Jpmorgan chase4.72M3.59%$1.88B
State street3.08M2.38%$1.41B
Geode capital management2.65M2.02%$1.06B
Baillie gifford2.60M1.98%$1.03B

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Fenghe fund management pte.218.70K4.90%$86.97M
Bellevue group446.52K4.23%$203.61M
Parkman healthcare partners87.69K4.17%$39.99M
Orbis allan gray1.95M3.82%$889.64M
Rosenblum silverman sutton s f inc /ca34.00K3.54%$15.50B
Orbimed advisors301.60K3.24%$137.53M
Palo alto investors lp32.32K2.73%$14.74M
Artia global partners lp34.57K2.50%$15.76M
Quantessence capital15.87K2.29%$7.24M
683 capital management122.90K2.26%$29.86M

Top Buyers

HolderShares% AssetsChange
Norges bank2.25M0.10%2.25M
Arrowstreet capital, limited partnership1.36M0.39%1.19M
Fmr16.77M0.40%961.10K
Qube research811.28K0.38%811.28K
Two sigma advisers, lp892.50K0.81%626.40K

Top Sellers

HolderShares% AssetsChange
T. rowe price investment management2.17M0.61%-2.11M
Regeneron pharmaceuticals---1.39M
Price t rowe associates inc /md/1.80M0.09%-1.34M
Dodge & cox2.32M0.57%-875.87K
Jane street group311.29K0.02%-647.46K

New Positions

HolderShares% AssetsChangeValue
Norges bank2.25M0.10%2.25M$895.82M
Susquehanna advisors group286.10K2.00%286.10K$130.46M
Fenghe fund management pte.218.70K4.90%218.70K$86.97M
Bank of america corp /de/83.50K0.00%83.50K$20.29M
Axa investment managers61.66K0.08%61.66K$28.12M

Sold Out

HolderChange
Rise advisors-1.00
Financial gravity asset management-1.00
Salem investment counselors-1.00
Bear mountain capital-1.00
Kohmann bosshard financial services-1.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Dec 31, 2025684-20.56%91,965,556-31.27%690.66%343-32.61%2325.45%
Sep 30, 202582219.83%128,435,377-3.80%990.93%48136.26%215-3.15%
Jun 30, 20256852.09%133,478,5513.70%1021.04%3541.14%22010.00%
Mar 31, 202528-95.52%1,770,848-98.63%10.01%11-96.63%10-94.71%
Dec 31, 2024603-0.33%129,230,8605.02%1001.10%315-2.78%1836.40%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Capital Group Growth Fnd of Amer Comp9.82M7.40%-120.09K
American Funds Growth Fund of Amer A9.82M7.40%-120.09K
Vanguard US Total Market Shares ETF4.07M3.15%54.28K
Vanguard Total Stock Mkt Idx Inv4.17M3.14%9.04K
VA CollegeAmerica Amcap 529A3.73M2.89%658.62K
Vanguard Mid Cap Index Institutional2.86M2.16%-14.93K
Invesco QQQ Trust2.83M2.13%-6.26K
American Funds New Perspective A2.39M1.80%-370.32K
Capital Group New Perspective Comp2.39M1.80%-370.32K
Capital Group AMCAP Composite2.21M1.67%-188.64K

Recent Insider Transactions


DateNameRoleActivityValue
Mar 02, 2026Poulton Jeffrey V. EVP, Chief Financial OfficerSell$176.80K
Mar 02, 2026Poulton Jeffrey V. EVP, Chief Financial OfficerSell$21.04K
Mar 02, 2026Poulton Jeffrey V. EVP, Chief Financial OfficerSell$115.92K
Mar 02, 2026Poulton Jeffrey V. EVP, Chief Financial OfficerSell$40.26K
Mar 02, 2026Poulton Jeffrey V. EVP, Chief Financial OfficerSell$148.76K

Insider Transactions Trends


DateBuySell
2026 Q1-180
2025 Q4-96
2025 Q3-80
2025 Q2-17
2025 Q1-152

ALNY Ownership FAQ


Who Owns Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals shareholders are primarily institutional investors at 69.96%, followed by 0.42% insiders and 29.62% retail investors. The average institutional ownership in Alnylam Pharmaceuticals's industry, Biotech Stocks , is 381.47%, which Alnylam Pharmaceuticals falls below.

Who owns the most shares of Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals’s largest shareholders are Fmr (16.77M shares, 12.93%), Capital world investors (16.3M shares, 12.40%), and Vanguard group (13.55M shares, 10.31%). Together, they hold 35.64% of Alnylam Pharmaceuticals’s total shares outstanding.

Does Blackrock own Alnylam Pharmaceuticals?

Yes, BlackRock owns 7.57% of Alnylam Pharmaceuticals, totaling 9.55M shares as of Jun 2024. This represents 0.05% of BlackRock's total assets, with a market value of 2.32B$. In the last quarter, BlackRock increased its holdings by 522.66K shares, a 5.79% change.

Who is Alnylam Pharmaceuticals’s biggest shareholder by percentage of total assets invested?

Fenghe fund management pte is Alnylam Pharmaceuticals’s biggest shareholder by percentage of total assets invested, with 4.90% of its assets in 218.7K Alnylam Pharmaceuticals shares, valued at 86.97M$.

Who is the top mutual fund holder of Alnylam Pharmaceuticals shares?

Capital Group Growth Fnd of Amer Comp is the top mutual fund holder of Alnylam Pharmaceuticals shares, with 7.40% of its total shares outstanding invested in 9.82M Alnylam Pharmaceuticals shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools